Focal adhesion kinase inhibitor BI 853520 inhibits cell proliferation, migration and EMT process through PI3K/AKT/mTOR signaling pathway in ovarian cancer

Springer Science and Business Media LLC - 2021
Hong Li1, Yizhi Gao2, Chen Ren1
1Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China
2Department of High School, Wuhan Maple Leaf International School, Wuhan, China

Tóm tắt

AbstractFocal adhesion kinase (FAK) activation has been reported to be associated with cell progression and metastasis in a wide variety of cancer cells. Target treatment by inhibiting FAK has achieved remarkable effects in several cancers, but the effect in ovarian cancer has not been reported. In this study, we determined the role and the underlying molecular mechanism of BI853520, a novel small chemical FAK inhibitor against ovarian cancer. Results show that phosphorylated FAK tyrosine 397 (p-FAK Y397) is highly expressed in ovarian cancer tumor tissues and cell lines (SKOV3 and OVCAR3). BI853520 treatment greatly suppresses cell proliferation, viability, migration, invasion, decreases anchorage-independent growth and motility in vitro. Besides, treatment with BI853520 increases biologic effects following combination with chemotherapy in ovarian cancer cell lines. In addition, BI853520 suppresses EMT in ovarian cancer cell lines. Mechanically, BI853520 treatment downregulates the activation of PI3K/AKT/mTOR signal pathway. Finally, mice model experiments confirm BI853520 treatment dramatically reduces tumor growth in vivo and suppresses the activation of PI3K/AKT/mTOR signal pathway. Taken together, our findings demonstrate that focal adhesion kinase inhibitor BI853520 inhibits cell proliferation, migration, invasion and EMT process through PI3K/AKT/mTOR signaling pathway in ovarian cancer, and BI853520 can offer a preclinical rationale for targeting repression of FAK in ovarian cancer.

Từ khóa


Tài liệu tham khảo

Hao H, Naomoto Y, Bao X, Watanabe N, Sakurama K, Noma K, Motoki T, Tomono Y, Fukazawa T, Shirakawa Y, Yamatsuji T, Matsuoka J, Wang ZG, Takaoka, . Focal adhesion kinase as potential target for cancer therapy (review). Oncol Rep. 2009;22(05):973–9.

Schaller MD. Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci. 2010;123(7):1007–13.

Troyanovsky SM. Mechanism of cell-cell adhesion complex assembly. Curr Opin Cell Biol. 1999;11(5):561–6.

Angevin E, Lopez-Martin JA, Lin CC, Gschwend JE, Harzstark A, Castellano D, et al. Phase I study of Dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res. 2013;19(5):1257–68.

Ding L, Congwei L, Bei Q, Tao Y, Ruiguo W, Heze Y, et al. mTOR: an attractive therapeutic target for osteosarcoma? Oncotarget. 2016;7(31):50805–13.

Boutahar N, Guignandon A, Vico L, Proust MHL. Title: mechanical strain on osteoblasts activates autophosphorylation of FAK and PYK2 tyrosine sites involved in ERK activation. Calcif Tissue Int. 2004;279(29):30588–99.

Clemente CFMZ, Xavier-Neto J, Costa APD, Consonni SR, Antunes JE, Rocco SA, et al. Focal adhesion kinase governs cardiac concentric hypertrophic growth by activating the AKT and mTOR pathways. J Mol Cell Cardiol. 2012;52(2):493–501.

Mabuchi S, Kuroda H, Takahashi R, Sasano T. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 2015;137(1):173–9.

Lee JJ, Loh K, Yap YS. PI3K/AKT/mTOR inhibitors in breast cancer. Cancer Biol Med. 2016;12(4):342–54.

Lian JH, Wang WH, Wang JQ, Zhang YH, Li Y. Microrna-122 promotes proliferation, invasion and migration of renal cell carcinoma cells through the PI3K/AKT signaling pathway. Asian Pac J Cancer Prev. 2013;14(9):5017–21.

Hu C, Chen Xu, Wen J, Gong L, Liu Z, Wang J, et al. Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo. Cancer Sci. 2017;108(7):1347–56.

Thanapprapasr D, Previs RA, Hu W, Ivan C, Armaiz-Pena GN, Dorniak PL, et al. PTEN expression as a predictor of response to focal adhesion kinase inhibition in uterine cancer. Mol Cancer Ther. 2015;14(6):1466–75.

Zhang J, He DH, Zajac-Kaye M, Hochwald SN. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle. 2014;13(19):3143–9.

Phadke MS, Sini P, Smalley KSM. The novel ATP-competitive MEK/Aurora Kinase inhibitor BI-847325 overcomes acquired BRAF inhibitor resistance through suppression of MCL-1 and MEK expression. Mol Cancer Ther. 2015;14(6):1354–64.

Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012;11(4):909–20.

Laszlo V, Valko Z, Ozsvar J, Kovacs I, Garay T, Hoda MA, et al. The FAK inhibitor BI853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. J Mol Med. 2018;97(2):231–42.

De Jonge M, Sahebjam S, Mathijssen RH, Razak A, Van, d. B. D., & Pronk, L. C., , et al. 396 A phase I, dose-finding study of BI853520, a potent and selective inhibitor of protein tyrosine kinase 2 in patients with advanced or metastatic solid tumors. Eur J Cancer. 2012;48(Suppl 6):120–1.

Hirt UA, Waizenegger IC, Schweifer N, Haslinger C, Gerlach D, Braunger J, et al. Efficacy of the highly selective focal adhesion kinase inhibitor BI853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype. Oncogenesis. 2018;7(2):21.

Huan Y, Silva MA, Hong L, Linlin Z, Pengyun L, Xia L, et al. Long noncoding RNA DQ786243 interacts with miR-506 and promotes progression of ovarian cancer through targeting CAMP responsive element binding protein 1. J Cell Biochem. 2018;119(12):9764–80.

Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005;6(1):56–68.

Hochwald SN. Focal adhesion kinase signaling and function in pancreatic cancer. Front Biosci. 2011;E3(2):750–6.

Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, et al. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog. 2007;46(6):488–96.

Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, et al. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol. 2012;30(13):1527–33.

Jones SF, Siu LL, Bendell JC, et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015;33(5):1100–7.

Prosperi JR, Yang FF, Goss KH. Mutation of the APC tumor suppressor stimulates breast cancer cell proliferation through hyperactivation of FAK/Src/JNK signaling. Cancer Res. 2011;71(24 Supplement): P2-02-02.

Hui C, Dongliang W, Yuling L. SASH1 inhibits cervical cancer cell proliferation and invasion by suppressing the FAK pathway. Mol Med Rep. 2016;13(4):3613–8.

Tanjoni I, Walsh C, Nam JO, Lim ST, Schlaepfer DD. Abstract 1204: FAK inhibition selectively promotes tumor cell apoptosis in three-dimensional environments and suppresses tumor cell metastasis. Can Res. 2010;70(8 Supplement):1204.

Xing Z, Zhong-Zhen G, Qiang YU. Activation of FAK promotes forming of lung carcinoma cell aggregation which inhibits cell apoptosis and enhances cell proliferation in suspension. J Sun Yat-sen Univ. 2004;25(3):195–9.

Thamilselvan V, Craig DH, Basson MD. FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway. FASEB J. 2007;21(8):1730–41.

Bai J, Liu GY, Zhu J, Zhao YZ, Wang Z, Chen F, et al. Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer. 2009;101(2):327–34.

Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Can Res. 2007;67(22):10976–83.

Shah NR, Tancioni I, Ward KK, Lawson C, Chen XL, Jean C, et al. Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecol Oncol. 2014;134(1):104–11.

Tanjoni I, Walsh C, Uryu S, et al. PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biol Ther. 2010;9(10):764–77.

Lehembre F, Yilmaz M, Wicki A, Schomber T, Strittmatter K, Ziegler D, et al. NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. EMBO J. 2008;27(19):2603–15.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Thông tin tác giả